About Promis Diagnostics
Promis Diagnostics is a company based in Pasadena (United States) founded in 2019. Promis Diagnostics has raised $10.8 million across 1 funding round from investors including KB Investment and Solidus Investment. The company has 9 employees. Promis Diagnostics offers products and services including EarlyTect BCD and COVID-19 and Flu Testing. Promis Diagnostics operates in a competitive market with competitors including Viome, Invitae, Color, Everlywell and IGM Biosciences, among others.
- Headquarter Pasadena, United States
- Employees 9
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website promisdx.com
- Social LinkedIn X Facebook Instagram
- Legal Name Promis Diagnostics, Inc.,
- Total Equity Funding$10.8M (USD)
in 1 rounds
- Latest Funding Round$10.8M (USD), Series A
Jan 2020
- InvestorsKB Investment
& 1 more
- Employee Count9
Products & Services of Promis Diagnostics
Promis Diagnostics offers a comprehensive portfolio of products and services, including EarlyTect BCD and COVID-19 and Flu Testing.
Noninvasive urine test for early bladder cancer detection with high accuracy.
Tests for detecting viral infections using biomarker-based methods.
Funding Insights of Promis Diagnostics
Promis Diagnostics has successfully raised a total of $10.8M through 1 strategic funding round. The most recent funding activity was a Series A round of $10.8 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.8M
- Total Rounds 1
- Last Round Series A — $10.8M
- First Round $10.8M
(Jan 2020)
- Investors Count 2
All 1 funding rounds of Promis Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $10.8M | Series A | – | KB Investment, Solidus Investment | – |
2 investors in total: 2 institutional.
Investors in Promis Diagnostics
Promis Diagnostics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include KB Investment and Solidus Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund investing in early-stage tech startups | 1990 | kbic.co.kr | Seoul, South Korea | |
- | – | solidusvc.com | - |
Investor details for Promis Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Promis Diagnostics
2 dated milestones of Promis Diagnostics across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Promis Diagnostics is founded.
- Funding First funding round of $10.8M.
Competitors of Promis Diagnostics
Promis Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Viome, Invitae, Color, Everlywell and IGM Biosciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viome.com | 2016 | Los Alamos, United States | $301.57M | 136 | Machine learning-based bioinformatics solutions for health insights are provided. | |
| invitae.com | 2010 | San Francisco, United States | $189.56M | 1,700 | Home-based genetic tests for detecting diseases are provided to individuals. | |
| color.com | 2013 | Burlingame, United States | $506.44M | 687 | Cancer care is delivered through a virtual clinic by Color. | |
| everlywell.com | 2014 | Austin, United States | $330M | 614 | At-home health tests for biomarkers, nutrition, and hormone analysis. | |
| igmbio.com | 2010 | Mountain View, United States | $102.67M | 181 | Antibodies for cancer and infectious disease treatments are developed. | |
| variantbio.com | 2018 | Brooklyn, United States | $127.74M | – | Personalized therapeutics are developed using genomic data for rare diseases. | |
| newtopia.com | 2008 | New York, United States | $13.1M | – | Health management platform is provided for employers and insurers. | |
| geneplanet.com | 2008 | Ljubljana, Slovenia | $34.02M | – | DNA-based personalized health and fitness recommendations are offered. | |
| check-cap.com | 2005 | Haifa, Israel | $9.88M | – | Developer of imaging capsules for colorectal cancer screening | |
| counsyl.com | 2007 | San Francisco, United States | $112.89M | 503 | DNA mapping for pre-pregnancy genetic testing, DNA and cancer screening |
Detailed competitors of Promis Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Promis Diagnostics
10 companies that operate in the same segment as Promis Diagnostics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Promis Diagnostics
Promis Diagnostics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Promis Diagnostics is headquartered in Pasadena, United States. It is registered at Pasadena, California, United States.
Promis Diagnostics is a funded company, having raised a total of $10.8M across 1 funding round to date. The company's 1st funding round was a Series A of $10.8M, raised on Jan 2020.
Promis Diagnostics has 9 employees.
Promis Diagnostics was founded in 2019 in Pasadena, United States, focusing on biotechnology for cancer detection. Non-invasive diagnostic platforms are being developed to identify biomarkers such as DNA methylation and DNA repair genes. Stool-based tests are utilized for colorectal cancer screening. Operations center on advancing these technologies to support early detection in the medical diagnostics sector.
Promis Diagnostics's top competitors include Viome, IGM Biosciences and Variant Bio.
Promis Diagnostics offers EarlyTect BCD and COVID-19 and Flu Testing.
Promis Diagnostics has 2 investors. Key investors include KB Investment, and Solidus Investment.
Promis Diagnostics operates through Promis Diagnostics, Inc.,.